Key facts
- 52-week range (closes)
- $725.17 – $995.69 Lowest close May 11, 2026, highest Mar 3, 2026; 251 daily closes to Oct 13, 2026 from Dalsna Finance's price archive
- Fiscal year ends
- March Fiscal 2026 ended Mar 31, 2026, from SEC filings
- In the S&P 500 since
- Jan 13, 1999 · All S&P 500 changes
- Analyst coverage
- 1 open price target from 1 firm: Wells Fargo Approved targets tracked here; see the analyst section below
McKesson Corporation (MCK) is trading up at $1,030.12 (+1.95%) on NYSE/NASDAQ, as of the latest quote. It is a S&P 500 constituent in the Health Care sector.
Analyst price targets on MCK
One firm's current price target on McKesson Corporation: $933 — 9% below the current $1.03k. Each is tracked to its date and scored the same way a member's call is.
- Wells Fargo $902 → $933 by Aug 2027 Aug 11, 2026 via Investing.com · Wells Fargo's track record
Targets published by research firms, extracted from the news, checked against independent reporting, and linked to their source. Where a firm did not state a horizon the target is tracked as 12 months, the industry convention; the rows where the firm set its own horizon are marked. Reported here as facts about what was published — not recommendations from Dalsna Finance, and no firm listed is affiliated with this site.
McKesson Corporation revenue & net income history (FY2017–FY2026)
| FY2017Mar 2017 | FY2018Mar 2018 | FY2019Mar 2019 | FY2020Mar 2020 | FY2021Mar 2021 | FY2022Mar 2022 | FY2023Mar 2023 | FY2024Mar 2024 | FY2025Mar 2025 | FY2026Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $198.5B | $208.4B | $214.3B | $231.1B | $238.2B | $264.0B | $276.7B | $309.0B | $359.1B | $403.4B |
| Growth (year over year) | +4.0% | +4.9% | +2.9% | +7.8% | +3.1% | +10.8% | +4.8% | +11.7% | +16.2% | +12.4% |
| Gross profit | $11.3B | $11.2B | $11.8B | $12.0B | $12.1B | $13.1B | $12.4B | $12.8B | $13.3B | $14.6B |
| Gross margin | 5.7% | 5.4% | 5.5% | 5.2% | 5.1% | 5.0% | 4.5% | 4.2% | 3.7% | 3.6% |
| Operating income | $7.12B | $762.0M | $886.0M | $2.49B | −$5.04B | $2.04B | $4.38B | $3.91B | $4.42B | $6.21B |
| Operating margin | 3.6% | 0.4% | 0.4% | 1.1% | −2.1% | 0.8% | 1.6% | 1.3% | 1.2% | 1.5% |
| Net income | $5.07B | $67.0M | $34.0M | $900.0M | −$4.54B | $1.11B | $3.56B | $3.00B | $3.29B | $4.76B |
| Net margin | 2.6% | 0.0% | 0.0% | 0.4% | −1.9% | 0.4% | 1.3% | 1.0% | 0.9% | 1.2% |
| EPS (diluted) | $22.73 | $0.32 | $0.17 | $4.95 | −$28.26 | $7.23 | $25.03 | $22.39 | $25.72 | $38.38 |
| Balance sheet | ||||||||||
| Cash and equivalents | $2.78B | $2.67B | $2.98B | $4.01B | $6.28B | $3.53B | $4.68B | $4.58B | $5.69B | $3.98B |
| Total assets | $61.0B | $60.4B | $59.7B | $61.2B | $65.0B | $63.3B | $62.3B | $67.4B | $75.1B | $82.3B |
| Total liabilities | $49.7B | $50.3B | $51.4B | $55.9B | $64.8B | $65.1B | $63.8B | $69.0B | $76.8B | $84.1B |
| Long-term debt | $7.30B | $6.75B | $7.26B | $6.33B | $6.41B | $5.08B | $4.63B | $5.58B | $4.46B | $5.26B |
| Shareholders' equity | $11.1B | $9.80B | $8.09B | $5.09B | −$21.0M | −$2.27B | −$1.86B | −$1.97B | −$2.07B | −$2.17B |
| Cash flow | ||||||||||
| Operating cash flow | $4.74B | $4.34B | $4.04B | $4.37B | $4.54B | $4.43B | $5.16B | $4.31B | $6.08B | $6.16B |
| Capital expenditure | $404.0M | $405.0M | $426.0M | $362.0M | $451.0M | $388.0M | $390.0M | $431.0M | $537.0M | $436.0M |
| Free cash flow | $4.34B | $3.94B | $3.61B | $4.01B | $4.09B | $4.05B | $4.77B | $3.88B | $5.55B | $5.72B |
| Dividends paid | $253.0M | $262.0M | $292.0M | $294.0M | $276.0M | $277.0M | $292.0M | $314.0M | $345.0M | $381.0M |
| Share buybacks | $2.31B | $1.71B | $1.64B | $1.93B | $742.0M | $3.52B | $3.64B | $3.02B | $3.15B | $4.75B |
| Q2 FY25Sep 2024 | Q3 FY25Dec 2024 | Q4 FY25†Mar 2025 | Q1 FY26Jun 2025 | Q2 FY26Sep 2025 | Q3 FY26Dec 2025 | Q4 FY26†Mar 2026 | Q1 FY27Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $93.7B | $95.3B | $90.8B | $97.8B | $103.2B | $106.2B | $96.3B | $105.4B |
| Growth (year over year) | +21.3% | +17.8% | +18.9% | +23.4% | +10.1% | +11.4% | +6.0% | +7.7% |
| Gross profit | $3.25B | $3.28B | $3.64B | $3.28B | $3.54B | $3.69B | $4.04B | $3.69B |
| Gross margin | 3.5% | 3.4% | 4.0% | 3.4% | 3.4% | 3.5% | 4.2% | 3.5% |
| Operating income | $578.0M | $1.22B | $1.59B | $1.04B | $1.41B | $1.62B | $2.15B | $1.32B |
| Operating margin | 0.6% | 1.3% | 1.8% | 1.1% | 1.4% | 1.5% | 2.2% | 1.3% |
| Net income | $241.0M | $879.0M | $1.26B | $784.0M | $1.11B | $1.19B | $1.68B | $614.0M |
| Net margin | 0.3% | 0.9% | 1.4% | 0.8% | 1.1% | 1.1% | 1.7% | 0.6% |
| EPS (diluted) | $1.87 | $6.95 | $9.90 | $6.25 | $8.92 | $9.59 | $13.62 | $5.15 |
| Balance sheet | ||||||||
| Cash and equivalents | $2.51B | $1.13B | $5.69B | $2.42B | $4.00B | $2.96B | $3.98B | $5.16B |
| Total assets | $72.4B | $71.1B | $75.1B | $81.3B | $84.2B | $84.2B | $82.3B | $88.3B |
| Total liabilities | $75.1B | $73.8B | $76.8B | $82.9B | $85.5B | $85.1B | $84.1B | $92.2B |
| Long-term debt | $5.69B | $4.42B | $4.46B | $6.53B | $6.01B | $5.42B | $5.26B | $8.43B |
| Shareholders' equity | −$3.02B | −$3.08B | −$2.07B | −$1.97B | −$1.74B | −$1.30B | −$2.17B | −$4.24B |
| Cash flow | ||||||||
| Operating cash flow | $2.10B | −$2.38B | $7.75B | −$918.0M | $2.42B | $1.23B | $3.42B | −$220.0M |
| Capital expenditure | $136.0M | $126.0M | $169.0M | $111.0M | $106.0M | $108.0M | $111.0M | $112.0M |
| Free cash flow | $1.96B | −$2.51B | $7.58B | −$1.03B | $2.31B | $1.12B | $3.31B | −$332.0M |
| Dividends paid | $80.0M | $92.0M | $91.0M | $90.0M | $89.0M | $101.0M | $101.0M | $102.0M |
| Share buybacks | $1.49B | $827.0M | $300.0M | $581.0M | $818.0M | $680.0M | $2.67B | $2.53B |
From McKesson Corporation's 10-K and 10-Q filings with the SEC; its fiscal year ends in March. Each period shows the latest figure the company has reported for it, including restatements. Net margin is our own calculation from those reported figures (net income ÷ revenue); it is left blank where revenue is zero or missing. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
McKesson Corporation vs the Health Care sector and the S&P 500
McKesson Corporation's latest reported figures next to the median of the other 59 S&P 500 Health Care companies and of the other 502 S&P 500 companies; each median is taken over the companies with a comparable figure (counts in the footnote). A median is the middle value, not an average, so one very large company does not move it.
| Measure | McKesson Corporation | Health Care (59 other S&P 500 companies) | S&P 500 (502 other companies) |
|---|---|---|---|
| Revenue growth, latest fiscal year | +12.4% | +7.1% | +7.0% |
| Net margin, latest fiscal year | 1.2% | 13.1% | 13.0% |
| Dividend per share, latest fiscal year | $3.17 | $2.43 | $2.40 |
| Share price change, 1 year | +30.8% | +22.0% | +7.5% |
McKesson Corporation: fiscal year ended March 2026, from its 10-K and 10-Q filings with the SEC. Medians computed October 20, 2026 from each company's latest annual filing (fiscal years ending between July 2025 and September 2026) and our price archive. Prices for every company, McKesson Corporation included, are the last regular-session prices of October 20, 2026; the 1-year change compares that price with each company's last close on or before October 20, 2025. Net margin and price change are our calculations from reported figures. Each median counts only the companies with a comparable figure (sector / S&P 500): revenue growth 59/496, net margin 59/496, dividend per share 32/349, 1-year price change 59/488; the reasons below can overlap. 14 are left out of the price figure because our archive holds no comparable close for them; dividend medians are among the 32 sector and 349 S&P 500 companies reporting a per-share dividend. The S&P 500 price figure is the middle company's change, not the index's return.
About McKesson Corporation
McKesson Corporation is an American publicly traded company that distributes pharmaceuticals and provides health information technology, medical supplies, and health management tools. The company delivers a third of all pharmaceutical products used or consumed in North America and employs over 80,000 employees. With $308.9 billion in 2024 revenue, it is the ninth-largest company by revenue in the United States and the nation's largest health care company. The company is headquartered in Irving, Texas. It is a component of the S&P 500 and is listed on the New York Stock Exchange, where it is traded under the ticker symbol "MCK".
- Headquarters
- Irving, Texas From SEC filings, Oct 2026
Recent News (1)
More Health Care stocks
- ISRG Intuitive Surgical
- JNJ Johnson & Johnson
- LH Labcorp
- LLY Lilly (Eli)
- MDT Medtronic
- MRK Merck & Co.
- MRNA Moderna
- MTD Mettler Toledo